![]() | |
Clinical data | |
---|---|
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C15H20N2O4 |
Molar mass | 292.335 g·mol−1 |
3D model ( JSmol) | |
|
Filaminast (code name WAY-PDA 641) [1] was a drug candidate developed by Wyeth-Ayerst. [2]: Table 2 It is a phosphodiesterase 4 inhibitor ( PDE4 inhibitor) and an analog of rolipram, which served as a prototype molecule for several development efforts. [3] [4]: 668, 678 It was discontinued after a Phase II trial showed that its therapeutic window was too narrow; it could not be dosed high enough without causing significant side effects (nausea and vomiting), which was a problem with the rolipram class of molecules. [4]: 678
![]() | |
Clinical data | |
---|---|
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C15H20N2O4 |
Molar mass | 292.335 g·mol−1 |
3D model ( JSmol) | |
|
Filaminast (code name WAY-PDA 641) [1] was a drug candidate developed by Wyeth-Ayerst. [2]: Table 2 It is a phosphodiesterase 4 inhibitor ( PDE4 inhibitor) and an analog of rolipram, which served as a prototype molecule for several development efforts. [3] [4]: 668, 678 It was discontinued after a Phase II trial showed that its therapeutic window was too narrow; it could not be dosed high enough without causing significant side effects (nausea and vomiting), which was a problem with the rolipram class of molecules. [4]: 678